Effects of melatonin on wortmannin-induced tau hyperphosphorylation

Acta Pharmacologica Sinica

Volumn 26, Issue 5, 2005, Pages 519-526

  Deng, Yan Qiu ^a   Xu, Guo Gang ^a   Duan, Ping ^a   Zhang, Qi ^a   Wang, Jian Zhi ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Alzheimer disease; Mela tonin; Tau protein; Wortmannin

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ALPHA TOCOPHEROL; CRYSTAL VIOLET; GLYCOGEN SYNTHASE; GLYCOGEN SYNTHASE KINASE 3; MALONALDEHYDE; MELATONIN; SUPEROXIDE DISMUTASE; TAU PROTEIN; TETRAZOLIUM; WORTMANNIN;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CELL LOSS; CELL VACUOLE; CELL VIABILITY; DRUG EFFECT; DRUG INDUCED DISEASE; ELECTRON MICROSCOPY; ENZYME ACTIVITY; LIPID PEROXIDATION; NICK END LABELING; NONHUMAN; OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION; RAT;

ANDROSTADIENES; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LIPID PEROXIDATION; MALONDIALDEHYDE; MELATONIN; NEUROBLASTOMA; PHOSPHORYLATION; SUPEROXIDE DISMUTASE; TAU PROTEINS; VITAMIN E;

EID: 18744415485     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2005.00102.x     Document Type: Article

References (41)

1. Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci 2001; 24: 1121-59.
2. Johnson GV, Hartigan JA. Tau protein in normal and Alzheimer's disease brain: an update. J Alzheimers Dis 1999; 1: 329-51.
3. Billingsley ML, Kincaid RL. Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem J 1997; 323: 577-91.
4. Maas T, Eidenmuller J, Brandt R. Interaction of tau with the neural membrane cortex is regulated by phosphorylation at sites that are modified in paired helical filaments. J Biol Chem 2000; 275: 15733-40.
5. Bhat RV, Budd Haeberlein SL, Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem 2004; 89: 1313-7.
6. Li X, Bijur GN, Jope RS. Glycogen synthase kinase-3β, mood stabilizers, and neuroprotection. Bipolar Disord 2002; 4: 137-44.
7. Bhat RV, Budd SL. GSK-3beta signalling: casting a wide net in Alzheimer's disease. Neurosignals 2002; 11: 251-61.
8. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, et al. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 1999; 58: 1010-9.
9. Liu SJ, Zhang AH, Li HL, Wang Q, Deng HM, Netzer WJ, et al. Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory. J Neurochem 2003; 87: 1333-44.
10. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991; 12: 151-80.
11. Zhang YC, Wang ZF, Wang Q, Wang YP, Wang JZ. Melatonin attenuates beta-amyloid-induced inhibition of neurofilament expression. Acta Pharmacol Sin 2004; 25: 447-51.
12. Li SP, Deng YQ, Wang XC, Wang YP, Wang JZ. Melatonin protects SH-SY5Y neuroblastoma cells from calyculin A-induced neurofilament impairment and neurotoxicity. J Pineal Res 2004; 36: 186-91.
13. Wang DL, Ling ZQ, Cao FY, Zhu LQ, Wang JZ. Melatonin attenuates isoproterenol-induced protein kinase an overactivation and tau hyperphosphorylation in rat brain. J Pineal Res 2004; 37: 11-6.
14. Kim BC, Shon BS, Ryoo YW, Kim SP, Lee KS. Melatonin reduces X-ray irradiation-induced oxidative damages in cultured human skin fibroblasts. J Dermatol Sci 2001; 26: 194-200.
15. Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 1974; 47: 469-74.
16. Lee CW, Lau KF, Miller CC, Shaw PC. Glycogen synthase kinase-3 beta-mediated tau phosphorylation in cultured cell lines. Neuroreport 2003; 14: 257-60.
17. Sun W, Qureshi HY, Cafferty PW, Sobue K, Agarwal-Mawal A, Neufield KD, et al. Glycogen synthase kinase-3beta is complexed with tau protein in brain microtubules. J Biol Chem 2002; 277: 11933-40.
18. Eldar-Finkelman H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med 2002; 8: 126-32.
19. Krasilnikov MA. Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation. Biochemistry (Mosc) 2000; 65: 59-67.
20. Liu SJ, Wang JZ. Alzheimer-like tau phosphorylation induced by wortmannin in vivo and its attenuation by melatonin. Acta Pharmacol Sin 2002; 23: 183-7.
21. Wang YP, Wang ZF, Zhang YC, Tian Qing, Wang JZ. Effect of amyloid peptides on serum withdrawal-induced cell differentiation and cell viability. Cell Res 2004; 14: 467-72.
22. Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol 2002; 156: 1051-63.
23. Munoz JP, Alvarez A, Maccioni RB. Increase in the expression of the neuronal cyclin-dependent protein kinase cdk-5 during differentiation of N2A neuroblastoma cells. Neuroreport 2000; 11: 2733-8.
24. Brandt R. Cytoskeletal mechanisms of neuronal degeneration. Cell Tissue Res 2001; 305: 255-65.
25. Lesort M, Blanchard C, Yardin C, Esclaire F, Hugon J. Cultured neurons expressing phosphorylated tau are more resistant to apoptosis induced by NMDA or serum deprivation. Brain Res Mol Brain Res 1997; 45: 127-32.
26. Jellinger KA. Cell death mechanisms in neurodegeneration. J Cell Mol Med 2001; 5: 1-17.
27. Atzori C, Ghetti B, Piva R, Srinivasan AN, Zolo P, Delisle MB, et al. Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J Neuropathol Exp Neurol 2001; 60: 1190-7.
28. Ferrer I, Blanco R, Carmona M, Ribera R, Goutan E, Puig B, et al. Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Brain Pathol 2001; 11: 144-58.
29. Marx J. Neuroscience. New leads on the 'how' of Alzheimer's disease. Science 2001; 293: 2192-4.
30. Grundman M, Grundman M, Delaney P. Antioxidant strategies for Alzheimer's disease. Proc Nutr Soc 2002; 61: 191-202.
31. Matsubara E, Shoji M, Murakami T, Kawarabayashi T, Abe K. Alzheimer's disease and melatonin. Int Congress Series 2003; 1252: 395-98.
32. Beyer CE, Steketee JD, Saphier D. Antioxidant properties of melatonin-an emerging mystery. Biochem Pharmacol 1999; 57: 1077.
33. Guillemin GJ, Brew BJ. Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease. Redox Rep 2002; 7: 199-206.
34. Cabrera J, Reiter RJ, Tan DX, Qi W, Sainz RM, Mayo JC, et al. Melatonin reduces oxidative neurotoxicity due to quinolinic acid: in vitro and in vivo findings. Neuropharmacology 2000; 39: 507-14.
35. Miranda S, Opazo C, Larrondo LF, Munoz FJ, Ruiz F, Leighton F, et al. The role of oxidative stress in the toxicity induced by amyloid beta-peptide in Alzheimer's disease. Prog Neurobiol 2000; 62: 633-48.
36. Montilla-Lopez P, Munoz-Agueda MC, Feijoo Lopez M, Munoz-Castaneda JR, Bujalance-Arenas I, Tunez-Finana I. Comparison of melatonin versus vitamin C on oxidative stress and antioxidant enzyme activity in Alzheimer's disease induced by okadaic acid in neuroblastoma cells. Eur J Pharmacol 2002; 451: 237-43.
37. Reiter RJ. Melatonin. Lowering the high price of free radicals. News Physiol Sci 2000; 15: 246-50.
38. Matsubara E, Bryant-Thomas T, Pacheco Quinto J, Henry TL, Poeggeler B, Herbert D, et al. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem 2003; 85: 1101-8.
39. Reiter RJ, Tan DX, Sainz RM, Mayo JC, Lopez-Burillo S. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 2002; 54: 12299-321.
40. Naji L, Carrillo-Vico A, Guerrero JM, Calvo JR. Expression of membrane and nuclear melatonin receptors in mouse peripheral organs. Life Sci 2004; 74: 2227-36.
41. Pappolla MA, Simovich MJ, Bryant-Thomas T, Chyan YJ, Poeggeler B, Dubocovich M, et al. The neuroprotective activities of melatonin against the Alzheimer beta-protein are not mediated by melatonin membrane receptors. J Pineal Res 2002; 32: 135-42.